Cart
sales@molnova.com
SM 16
CAS No. 614749-78-9
SM 16( —— )
Catalog No. M19909 CAS No. 614749-78-9
SM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 147 | In Stock |
|
| 25MG | 264 | In Stock |
|
| 50MG | 419 | In Stock |
|
| 100MG | 617 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSM 16
-
NoteResearch use only, not for human use.
-
Brief DescriptionSM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
-
DescriptionSM 16 is a ALK5/ALK4 kinase inhibitor (Ki: 10/1.5 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK4| ALK5
-
Research AreaCancer
-
IndicationCancer
Chemical Information
-
CAS Number614749-78-9
-
Formula Weight430.5
-
Molecular FormulaC25H26N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 60 mg/mL
-
SMILESCc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C12CCC(CC1)(CC2)C(N)=O
-
Chemical Name4-[4-(13-Benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Suzuki E et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 2007 Mar 1;67(5):2351-9.
molnova catalog
related products
-
Tyrphostin AG 879
Tyrphostin AG 879 effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.
-
GSK1838705A
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
-
CPI-169
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
